1988 January-September

Morehead State Athletics press releases from January to September of 1988

Statement, March/April 1988

Statement Magazine of Morehead State University from March and April of 1988

Wood Hill Herald 1963-03-01, (March, 1963)

Third issue, Editorial reporting issues with police protection and contact with the Sheriff department; Medical Center (Park Forest) opens near Wood Hill at 23450 Western Avenue, 2nd annual Spring Music Festival was presented by Crete- Monee Unit 201-U School

The Lindenwood College Bulletin, June 1918

Lindenwood College alumni magazine.https://digitalcommons.lindenwood.edu/alumni_bulletin/1469/thumbnail.jp

Harding College Course Catalog 1926-1927

Catalog of Harding College 1926-1927https://scholarworks.harding.edu/catalogs/1036/thumbnail.jp

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer.

Preclinical studies demonstrate that epidermal growth factor receptor (EGFR) signals through both kinase-dependent and independent pathways and that combining a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic. We conducted a dose-escalation, phase I study combining erlotinib, cetuximab, and bevacizumab. The subset of patients with metastatic colorectal cancer was analyzed for safety and antitumor activity. Forty-one patients with heavily pretreated metastatic colorectal cancer received treatment on a range of dose levels. The most common treatment-related grade ≥2 adverse events were rash (68%), hypomagnesemia (37%), and fatigue (15%). Thirty of 34 patients (88%) treated at the full FDA-approved doses of all three drugs tolerated treatment without drug-related dose-limiting effects. Eleven patients (27%) achieved stable disease (SD) ≥6 months and three (7%) achieved a partial response (PR) (total SD>6 months/PR= 14 (34%)). Of the 14 patients with SD≥6 months/PR, eight (57%) had received prior sequential bevacizumab and cetuximab, two (5%) had received bevacizumab and cetuximab concurrently, and four (29%) had received prior bevacizumab but not cetuximab or erlotinib (though three had received prior panitumumab). The combination of bevacizumab, cetuximab, and erlotinib was well tolerated and demonstrated antitumor activity in heavily pretreated patients with metastatic colorectal cancer

State Normal School Journal, February 4, 1921

This issue contains an article by Ralph E. Tieje about underprivileged neighborhoods (i.e., slums) in New York, as well as articles about the men\u27s basketball trip to central and western Washington, the upcoming women\u27s basketball schedule, a pen pal project between fourth graders in the Training school and a school in Hong Kong, and the activities of the debate team, which includes selecting a name for the Normal School\u27s athletic teams.https://dc.ewu.edu/student_newspapers/1220/thumbnail.jp